Geron (GERN) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verastem (VSTM) has outperformed Geron (GERN) over the past year, losing 9.3% versus a loss of 11.6%. Over five years, GERN leads with a -13.5% price change compared with -74.7% for VSTM. Geron is the larger company by market cap ($787.0 million vs $758.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GERN | VSTM |
|---|---|---|
| Share price | $1.23 | $8.38 |
| Market cap | $787.03M | $758.92M |
| 1-day change | +0.41% | +3.33% |
| YTD return | -7.58% | +8.55% |
| 1-year return | -11.59% | -9.31% |
| 5-year return | -13.48% | -74.70% |
| Forward P/E | 30.63 | — |
| EPS (TTM) | $-0.11 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.01 | $10.82 |
| 52-week low | $1.04 | $3.43 |
| Distance from 52-week high | -39.05% | -22.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +246.94% | +79.00% |
| Average volume | 10.06M | 2.24M |
| Shares outstanding | 642.47M | 90.56M |
| Employees | 258 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
GERN vs VSTM FAQ
Which is bigger, Geron or Verastem?
Geron (GERN) is larger, with a market capitalization of $787.03M compared with $758.92M for Verastem (VSTM).
Which stock has performed better over the past year, GERN or VSTM?
VSTM returned -9.31% over the past 12 months, compared with -11.59% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Geron and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.